445 related articles for article (PubMed ID: 25724523)
1. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
[TBL] [Abstract][Full Text] [Related]
2. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
3. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
4. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
Tonlaar N; Galoforo S; Thibodeau BJ; Ahmed S; Wilson TG; Yumpo Cardenas P; Marples B; Wilson GD
Radiother Oncol; 2017 Sep; 124(3):504-512. PubMed ID: 28823407
[TBL] [Abstract][Full Text] [Related]
6. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
Chen YH; Wei MF; Wang CW; Lee HW; Pan SL; Gao M; Kuo SH; Cheng AL; Teng CM
Cancer Lett; 2015 Feb; 357(2):582-90. PubMed ID: 25497009
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Cerniglia GJ; Karar J; Tyagi S; Christofidou-Solomidou M; Rengan R; Koumenis C; Maity A
Mol Pharmacol; 2012 Dec; 82(6):1230-40. PubMed ID: 22989521
[TBL] [Abstract][Full Text] [Related]
8. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
[TBL] [Abstract][Full Text] [Related]
9. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
10. The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells.
Glorieux M; Dok R; Nuyts S
Sci Rep; 2020 Oct; 10(1):16208. PubMed ID: 33004905
[TBL] [Abstract][Full Text] [Related]
11. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
[TBL] [Abstract][Full Text] [Related]
12. PDK1 Mediates
Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
[TBL] [Abstract][Full Text] [Related]
15. PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair.
Xie Y; Liu C; Zhang Y; Li A; Sun C; Li R; Xing Y; Shi M; Wang Q
PLoS One; 2021; 16(10):e0258817. PubMed ID: 34665844
[TBL] [Abstract][Full Text] [Related]
16. The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells.
Hayman TJ; Wahba A; Rath BH; Bae H; Kramp T; Shankavaram UT; Camphausen K; Tofilon PJ
Clin Cancer Res; 2014 Jan; 20(1):110-9. PubMed ID: 24198241
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
Gil del Alcazar CR; Hardebeck MC; Mukherjee B; Tomimatsu N; Gao X; Yan J; Xie XJ; Bachoo R; Li L; Habib AA; Burma S
Clin Cancer Res; 2014 Mar; 20(5):1235-48. PubMed ID: 24366691
[TBL] [Abstract][Full Text] [Related]
18. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
19. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma.
Liao J; Jin H; Li S; Xu L; Peng Z; Wei G; Long J; Guo Y; Kuang M; Zhou Q; Peng S
J Exp Clin Cancer Res; 2019 Nov; 38(1):454. PubMed ID: 31694662
[TBL] [Abstract][Full Text] [Related]
20. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
